Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0378)
Drug Name
Copanlisib
Synonyms
Copanlisib; Copanlisib (BAY 80-6946); WI6V529FZ9; 1032568-63-0; 2-Amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-5-pyrimidinecarboxamide; Aliqopa; 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide; AK172384; BAY 80-6946; BAY 80-6946 (Copanlisib); BAY-80-6946; BAY80-6946; UNII-WI6V529FZ9
Indication Follicular lymphoma [ICD11: 2A80] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 480.5 Topological Polar Surface Area 140
Heavy Atom Count 35 Rotatable Bond Count 7
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 9
Cross-matching ID
PubChem CID
135565596
CAS Number
1032568-63-0
TTD Drug ID
D0S5LD
Formula
C23H28N8O4
Canonical SMILES
COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5
InChI
1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)
InChIKey
MWYDSXOGIBMAET-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Copanlisib metabolite M455 DM003724 N. A. Multi-steps Reaction - Ring cleavage; Dealkylation 1 [3]
Copanlisib metabolite M483a DM003725 N. A. Reduction - Reduction 1 [3]
Copanlisib metabolite M483b DM003726 N. A. Multi-steps Reaction - Morpholine ring cleavage; Dealkylation 1 [3]
Copanlisib metabolite M495 DM003723 N. A. Oxidation - Alpha-Oxidationn 1 [3]
Copanlisib metabolite M497a DM003721 N. A. Oxidation - Hydrolyzationn 1 [3]
Copanlisib metabolite M497b DM003722 N. A. Oxidation - Alpha-Hydrolyzationn 1 [3]
Copanlisib metabolite M499 DM003727 N. A. Multi-steps Reaction - Reduction; N-oxidation 1 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR004110 Copanlisib Copanlisib metabolite M497a Oxidation - Hydrolyzationn Unclear [3]
MR004111 Copanlisib Copanlisib metabolite M497b Oxidation - Alpha-Hydrolyzationn Unclear [3]
MR004112 Copanlisib Copanlisib metabolite M495 Oxidation - Alpha-Oxidationn Unclear [3]
MR004113 Copanlisib Copanlisib metabolite M455 Multi-steps Reaction - Ring cleavage; Dealkylation Unclear [3]
MR004114 Copanlisib Copanlisib metabolite M483a Reduction - Reduction Unclear [3]
MR004115 Copanlisib Copanlisib metabolite M483b Multi-steps Reaction - Morpholine ring cleavage; Dealkylation Unclear [3]
MR004116 Copanlisib Copanlisib metabolite M499 Multi-steps Reaction - Reduction; N-oxidation Unclear [3]
⏷ Show the Full List of 7 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A1 (CYP1A1) DME0006 Homo sapiens
CP1A1_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
References
1 Copanlisib was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
3 Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.